(From The Wall Street Journal)
In dollar terms, much of the sales came at a single company, Moderna, maker of one of two Covid-19 vaccines authorized for use in the U.S. Executives and a director there sold more than $321 million of their stock in more than 700 transactions. Merck MRK -0.77%& Co. insiders sold $58 million of their shares. At Novavax Inc.,NVAX +7.28%executives sold more than $40 million of their shares after the company’s vaccine hit milestones in August and September.
Click this link for the original source of this article.
This content is courtesy of, and owned and copyrighted by, https://www.ac2news.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.